Ionis Pharmaceuticals (IONS) announced that the FDA has accepted for priority review the supplemental new drug application for olezarsen for severe hypertriglyceridemia. The FDA has set a Prescription Drug User Fee Act target action date of June 30.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $77 from $73 at Stifel
- Ionis Pharmaceuticals Earnings Call Highlights Surging Momentum
- Ionis Pharmaceuticals: Accelerating Commercial Momentum, Conservative Guidance, and Late-Stage Pipeline Catalysts Underpin Buy Rating
- Ionis Pharmaceuticals: Strong 4Q25 Beat and Catalyst-Rich 2026 Underpin Raised Buy Rating and $103 Target
- Ionis Pharmaceuticals price target raised to $103 from $90 at Needham